Clinical trials sponsored by Tianjin Medical University Second Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Tianjin Medical University Second Hospital

• Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis
  NCT06536725 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 2 locations
• Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
  NCT07170293 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
  NCT06663007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
  NCT07179783 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location

Common questions

How many trials is Tianjin Medical University Second Hospital recruiting for?

Tianjin Medical University Second Hospital is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.